Forvis Mazars Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Forvis Mazars Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$255K	Buy	488 +42	+9%	+$21.5K	﹤0.01%	392
2026 Q2	$222K	Sell	446 -72	-14%	-$31.9K	﹤0.01%	416
2026 Q1	$231K	Buy	518 +16	+3%	+$7.46K	﹤0.01%	384
2025 Q4	$228K	Sell	502 -90	-15%	-$38.8K	﹤0.01%	386
2025 Q3	$232K	Sell	592 -1,008	-63%	-$421K	﹤0.01%	384
2025 Q2	$712K	Buy	1,600 +152	+10%	+$70K	0.02%	239
2025 Q1	$702K	Buy	+1,448	New	+$675K	0.02%	239
2020 Q4	–	Sell	-847	Closed	-$230K	–	361
2020 Q3	$230K	Buy	847 +35	+4%	+$9.7K	0.01%	294
2020 Q2	$236K	Buy	+812	New	+$220K	0.02%	278

Other funds holding VRTX

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Forvis Mazars Wealth Advisors's VRTX Position: Q3 2026 in Review

Forvis Mazars Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 9.4% in Q3 2026, buying an estimated $21.5K and bringing the position to 488 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #392.

Forvis Mazars Wealth Advisors first reported a position in VRTX in Q2 2020 and has held it in 9 quarters since. The position peaked at $712K in Q2 2025. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Forvis Mazars Wealth Advisors held 488 shares of Vertex Pharmaceuticals worth $255K as of Q3 2026.
Forvis Mazars Wealth Advisors bought 42 Vertex Pharmaceuticals shares in Q3 2026, an estimated $21.5K.
Vertex Pharmaceuticals made up ﹤0.01% of Forvis Mazars Wealth Advisors's portfolio in Q3 2026, its #392 holding.
Forvis Mazars Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 9 quarters since.
Forvis Mazars Wealth Advisors's Vertex Pharmaceuticals position peaked at $712K in Q2 2025.
1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Forvis Mazars Wealth Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.